Jyong Biotech rises on prostate cancer drug mid‑stage trial data
30/01/2026 13:43
** Shares of drugmaker Jyong Biotech MENS.O rise 2.68% to $2.63 premarket ** Co says its experimental drug, MCS‑8, helped reduce risk of prostate cancer — a disease caused by abnormal cell growth in the prostate gland ** Co says men on MCS‑8 had a 27% lower chance of developing prostate cancer vs placebo in a mid‑stage trial ** Trial also showed potential benefit for cholesterol control, with patients seeing lower total cholesterol, per co ** Co says no serious side effects reported; long‑term use did not affect liver, kidney or blood pressure ** MENS is considering expanding use of MCS‑8 for high cholesterol and heart disease, co says ** Shares up ~43% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))